Long-Term Prognostic Impact of Estimated Glomerular Filtration Rate on Admission in Patients Hospitalized for Acute Heart Failure

Rafael de la Espriella, Jorge Navarro, Anna Mollar, Luis D’Marco, Patricia Palau, Gema Miñana, Pau Llácer, Enrique Santas, Raquel Heredia, Miguel González, José Luis Górriz, Pau Codina, Javier Díez, Antoni Bayés-Genís, Julio Núñez

Cardiology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain; Department of Medicine, Universitat de Valencia, Valencia, Spain; Nephrology Department, Hospital Clínico Universitario de Valencia, Universitat de València. Valencia, INCLIVA, Valencia, Spain; Internal Medicine Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; Cardiology Department and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain; Program of Cardiovascular Diseases, Center of Applied Medical Research, University of Navarra, Pamplona, Spain; Centro de investigación biomédica en red (CIBER) Cardiovascular, Madrid, Spain

Keywords
Acute heart failure · Glomerular filtration rate · Mortality · Prognosis · Readmissions

Abstract
Introduction: Although small-sample size studies have shown that basal alterations of estimated glomerular filtration rate (eGFR) are related to short- and mid-term higher mortality in acute heart failure (AHF), there is scarce information on the influence of an altered eGFR on long-term mortality and readmissions. Therefore, this multicenter study sought to investigate the relationship between eGFR on admission for AHF and both long-term mortality and readmissions in a large sample of patients. Methods: We retrospectively evaluated 4,595 patients consecutively discharged after admission for AHF at three tertiary-care hospitals from January 1, 2008, to January 1, 2020. To investigate the effect of eGFR on admission with long-term morbimortality, we stratified the patients according to four eGFR categories: <30 mL·min⁻¹·1.73 m⁻² (G4 and G5 patients, n = 534), 30–44 mL·min⁻¹·1.73 m⁻² (G3b patients, n = 882), 45–59 mL·min⁻¹·1.73 m⁻² (G3a patients, n = 1,080), and ≥60 mL·min⁻¹·1.73 m⁻² (G1 and G2 patients, n = 2,099). eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation within the first 24 h following admission. Results: At a median follow-up of 2.20 years, multivariate analyses revealed that compared to G1 and G2 patients, G4 and G5 patients exhibited a higher risk of all-cause (HR = 1.15, 95% CI: 1.02–1.30, p = 0.020) and cardiovascular (HR = 1.20, 95% CI: 1.04–1.39, p = 0.013) mortality. Similarly, multivariate analyses also showed that the lower the eGFR, the higher the risk of readmissions. In fact, compared to G1 and G2 patients, G4 and G5 patients displayed signifi-
cantly increased incident rate ratios of total all-cause (28%), CV (26%), and HF-related (30%) readmissions. **Conclusion:** Data from this large study provide evidence that an eGFR below 30 mL·min⁻¹·1.73 m⁻² on admission could be an independent predictor for long-term mortality and readmissions in patients with AHF.

© 2022 The Author(s).
Published by S. Karger AG, Basel

**Introduction**

Acute heart failure (AHF) is often accompanied by multiple comorbidities, which adversely affect outcomes and may complicate management [1]. Among them, chronic kidney disease (CKD) is one of the most relevant comorbidities, affecting up to 50% of AHF patients with either a preserved or reduced ejection fraction [2, 3]. In addition to impaired baseline kidney function, the estimated glomerular filtration rate (eGFR) is highly dynamic during worsening heart failure (HF) episodes, with substantial individual heterogeneity in eGFR trajectories during hospitalization [4]. Nonetheless, such heterogeneity in eGFR does not appear to provide additional prognostic information to baseline eGFR [4]. Furthermore, there is scarce information on the influence of reduced eGFR on admission and long-term prognosis in patients with AHF, with few small retrospective studies focused on short-term mortality [5]. Thus, this multicenter study sought to investigate the relationship between eGFR on admission for AHF and both long-term mortality and readmissions in a large sample of patients.

**Methods**

We retrospectively evaluated a consecutive cohort of 4,812 patients admitted with AHF at three tertiary-care hospitals in Valencia, Spain, from January 1, 2009, to January 1, 2020. All patients with a final diagnosis of AHF (either new-onset or decompensated chronic HF) as the principal diagnosis were eligible. After the exclusion of 217 in-hospital deaths during the index admission, the final study sample included 4,595 patients. Data were collected on patient demographics, medical history, vital signs, and physical examination at presentation, laboratory tests, 12-lead electrocardiogram, echocardiographic parameters, and treatments at discharge, using pre-established registry questionnaires. This study complied with the Declaration of Helsinki and was approved by the local institutional review committees.

Biomarkers were assessed together within the first 24 h after admission and analyzed in the local laboratory at each center. eGFR was calculated based on the creatinine levels using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [6].

Patients who died during index admission were excluded from this analysis. For the remaining cohort, patient follow-up continued until death through January 1, 2020. After discharge, a multidisciplinary HF team followed patients in close collaboration with primary care physicians. Based on the first evaluation and treatment upon discharge, therapeutic strategies and monitoring were individualized according to clinical guidelines.

After discharge, all-cause deaths, cardiovascular (CV) deaths, and the total burden of rehospitalizations (all-cause, CV-, and HF-related admissions) were registered. Deaths of CV etiology included sudden death, HF death, and deaths attributable to other cardiovascular causes (such as myocardial infarction, stroke, etc.) [7]. Unknown causes of death were those that could not be classified as CV or non-CV due to limited information (the only available information was “patient died”) and were also considered CV deaths [7]. Only unplanned readmissions were included. HF-related readmissions were those in which worsening HF or AHF was the primary diagnosis at discharge. CV related were those admissions due to worsening HF, acute myocardial infarction, unstable angina, stroke or transient ischemic attack, cardiarrhythmias, or peripheral artery disease. Information regarding patients’ survival status was ascertained at each hospitalization, during office visits, or through a review of electronic medical records. The person in charge of endpoint adjudications was blinded to the exposure variable and patients’ clinical data.

Patients were stratified according to eGFR categories into four clinical strata: <30 mL·min⁻¹·1.73 m⁻² (G4 and G5 categories); 30–44 mL·min⁻¹·1.73 m⁻² (G3b category); 45–59 mL·min⁻¹·1.73 m⁻² (G3a category); and ≥60 mL·min⁻¹·1.73 m⁻² (G1 and G2 categories) [8]. Continuous variables are presented as mean (± standard deviation) or median (interquartile range), as appropriate. Categorical variables are expressed as percentages. Comparisons across eGFR categories were performed by χ² test for categorical variables. For continuous variables, one-way analysis of variance and Kruskal-Wallis test were used for those variables with a parametric and nonparametric distribution, respectively.

The association of variables with time to all-cause mortality (AC mortality) was assessed using multivariate Cox proportional-hazard regression models. For estimating the multivariate risk of CV death, we used a Fine and Gray regression model by accounting for other causes of death as competing events. Risk estimates for the Cox and the Fine and Gray analyses were expressed as hazard or sub-distribution hazard ratios, respectively, with their 95% confidence intervals (95% CIs). A descriptive analysis of recurrent events was performed by counting the number of hospitalizations during follow-up. Crude incidence rates (expressed as the number of rehospitalizations per 100 person-years) were calculated for every readmission endpoint. For recurrent events, we used bivariate negative binomial regression models that simultaneously model the number of readmissions (as counts) and mortality (as a terminal event). Regression estimates for both outcomes are mutually adjusted utilizing shared frailty (accounting for the positive correlation between the two outcomes) [9]. Estimates of risk were expressed as incidence rate ratios. For the multivariate regression models, candidate covariates were chosen based on prior medical knowledge/biological plausibility independent of their p value. The linearity assumption for all continuous variables was simultaneously tested, and the variable transformed, if appropriate, with fractional polynomials. Then, reduced and parsimonious models were derived by using backward stepwise selection. Discriminative.
Table 1. Baseline characteristics across eGFR categories

| Variable                        | G1 and G2 (eGFR ≥60 mL·min⁻¹·1.73 m⁻²) | G3a (eGFR 45–59 mL·min⁻¹·1.73 m⁻²) | G3b (eGFR 30–44 mL·min⁻¹·1.73 m⁻²) | G4 and G5 (eGFR <30 mL·min⁻¹·1.73 m⁻²) | p value |
|--------------------------------|----------------------------------------|------------------------------------|------------------------------------|----------------------------------------|---------|
| N                              | 2,099                                  | 1,080                              | 882                                | 534                                    |         |
| **Demographics and medical history** |                                         |                                    |                                    |                                        |         |
| Age, years                     | 70.1 (12.3)                            | 76.4 (9.2)                         | 77.9 (8.5)                         | 77.9 (8.5)                             | <0.001  |
| Male                           | 1,174 (55.9)                           | 583 (54.0)                         | 433 (49.1)                         | 258 (48.3)                             | <0.001  |
| First HF admission             | 1,581 (75.3)                           | 708 (65.6)                         | 537 (60.9)                         | 322 (60.3)                             | <0.001  |
| NYHA III-IV                    | 264 (12.6)                             | 169 (15.6)                         | 192 (21.8)                         | 142 (26.6)                             | <0.001  |
| DM                             | 841 (40.1)                             | 480 (44.4)                         | 407 (46.1)                         | 281 (52.6)                             | <0.001  |
| Hypertension                   | 1,516 (72.2)                           | 901 (83.4)                         | 748 (84.8)                         | 478 (89.5)                             | <0.001  |
| Ischemic heart disease         | 583 (27.9)                             | 399 (37.1)                         | 329 (37.3)                         | 218 (41.0)                             | <0.001  |
| Charlson’s index*              | 1.0 (0.0, 2.0)                         | 2.0 (1.0, 3.0)                     | 3.0 (1.0, 4.0)                     | 4.0 (3.0, 5.0)                         | <0.001  |
| **Vital signs, electrocardiogram, echocardiogram** |                                           |                                    |                                    |                                        |         |
| Heart rate, bpm                | 99.6 (27.3)                            | 96.8 (28.5)                         | 91.5 (27.6)                         | 88.6 (25.4)                            | <0.001  |
| SBP, mm Hg                     | 145.7 (29.9)                           | 143.9 (32.0)                       | 141.9 (31.7)                       | 141.3 (31.1)                           | <0.001  |
| DBP, mm Hg                     | 83.2 (18.5)                            | 79.7 (19.4)                         | 76.5 (18.4)                         | 74.1 (16.6)                            | <0.001  |
| Atrial fibrillation            | 952 (45.4)                             | 522 (48.3)                         | 399 (45.2)                         | 239 (44.8)                             | 0.354   |
| LVEF*                          | 49.1 (15.6)                            | 50.0 (14.7)                         | 50.8 (15.0)                         | 50.8 (14.8)                            | 0.011   |
| **HF phenotype**               |                                        |                                    |                                    |                                        |         |
| HFrEF                          | 718 (34.2)                             | 328 (30.4)                         | 252 (28.6)                         | 140 (26.2)                             | 0.002   |
| HFmrEF                         | 277 (13.2)                             | 156 (14.4)                         | 132 (15.0)                         | 95 (17.8)                              |         |
| HFpEF                          | 1,104 (52.6)                           | 596 (55.2)                         | 498 (56.5)                         | 299 (56.0)                             |         |
| **Blood tests**                |                                        |                                    |                                    |                                        |         |
| Creatinine, mg/dL              | 0.9 (0.2)                              | 1.2 (0.2)                          | 1.5 (0.3)                          | 2.5 (1.0)                              | <0.001  |
| BUN, mg/dL                     | 24.9 (9.3)                             | 31.6 (10.3)                        | 38.4 (13.6)                        | 52.9 (18.6)                            | <0.001  |
| Serum sodium, mEq/L            | 138.4 (4.3)                            | 138.6 (4.4)                        | 138.6 (4.5)                        | 138.1 (4.6)                            | 0.038   |
| Serum potassium, mEq/L         | 4.2 (0.5)                              | 4.3 (0.5)                          | 4.5 (0.7)                          | 4.6 (0.7)                              | <0.001  |
| Hemoglobin, g/dL               | 12.9 (1.9)                             | 12.5 (1.9)                         | 12.1 (2.0)                         | 11.4 (1.8)                             | <0.001  |
| CA125*, U/mL                   | 49.0 (21.4, 115.0)                     | 50.5 (21.8, 115.0)                 | 48.8 (22.4, 104.0)                 | 50.6 (25.0, 102.0)                     | 0.818   |
| NT-proBNP*, pg/mL              | 2,514.0 (1,368.0, 4,713.6)             | 3,580.6 (2,117.2, 6,649.4)         | 4,888.9 (2,625.0, 8,830.0)         | 8,337.0 (4,702.2, 15,779.7)            | <0.001  |
| **Treatment at discharge**     |                                        |                                    |                                    |                                        |         |
| RASI                           | 1,547 (73.7)                           | 774 (71.7)                         | 549 (62.2)                         | 254 (47.6)                             | <0.001  |
| Beta-blockers                  | 1,505 (72.3)                           | 761 (70.7)                         | 582 (66.4)                         | 359 (68.4)                             | 0.011   |
| MRA                            | 975 (46.5)                             | 469 (43.4)                         | 340 (38.5)                         | 143 (26.8)                             | <0.001  |
| Diuretics                      | 1,982 (95.2)                           | 1,042 (96.8)                       | 863 (98.3)                         | 506 (95.5)                             | <0.001  |
| FED, mg                        | 60.0 (40.0, 80.0)                      | 80.0 (40.0, 80.0)                  | 80.0 (40.0, 80.0)                  | 80.0 (40.0, 120.0)                     | <0.001  |

Data given as n (%), mean (SD), or median (IQR)*. eGFR, estimated glomerular filtration rate; HF, heart failure; NYHA, New York Heart Association; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure; BUN, blood urea nitrogen; CA125, carbohydrate antigen 125; NT-proBNP, amino-terminal pro-brain natriuretic peptide; LVEF, left ventricular ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; RASI, renin-angiotensin system inhibitors; MRA, mineralocorticoid receptor antagonist; FED, furosemide-equivalent doses.
The abilities of the multivariate models were evaluated with Harrell’s c-statistics. The final multivariate model for AC mortality included the following covariates: age, gender, prior HF admission, type 2 diabetes, heart rate, systolic blood pressure, left ventricular ejection fraction (LVEF), hemoglobin, amino-terminal pro-brain natriuretic peptide (NT-proBNP), antigen carbohydrate 125, and treatment at discharge (furosemide-equivalent doses, beta-blockers, mineralocorticoid receptor antagonists, and renin-angiotensin system inhibitors). The same set of covariates was used to estimate the multivariate risk of CV death, number of hospitalizations for all causes, CV-related causes, and HF-related causes.

We set a two-sided \( p \)-value of <0.05 as the threshold for statistical significance. Stata 15.1 (Stata Statistical Software, Release 15 [2017]; StataCorp LP, College Station, TX, USA) was used for this analysis.

**Results**

The total cohort’s mean age was 74 ± 11.2 years, 46.7% were female, and 54.3% had HFpEF. The mean of blood urea nitrogen, creatinine, and eGFR was 32.3 ± 14.9 mg/dL, 1.3 ± 0.7 mg/dL, and 58.3 ± 22.9 mL·min⁻¹·1.73 m⁻², respectively.

The distribution of the sample across eGFR categories was 2,149 (45.7%) G1 and G2 categories, 1,080 (23.5%) G3a category, 882 (19.2%) G3b category, and 534 (11.6%) G4 and G5 categories. As shown in Table 1, patients with eGFR categories G4 and G5 had a worse baseline risk profile. The majority of these patients were women, with a higher prevalence of T2DM and hypertension. Furthermore, 56% had preserved LVEF, presented worst New York Heart Association (NYHA) functional class, showed higher NT-proBNP values, and lower Hb levels. Likewise, these patients were less likely to be treated with renin-angiotensin system inhibitors and mineralocorticoid receptor antagonist.

At a median follow-up of 2.20 years (p25:0.74–p75:4.71), 2,257 (15.2 per 100 person-years) and 1,611 (10.9 per 100 person-years) all-cause and CV deaths were registered in those discharged alive from the hospitalization index \( (n = 4,595) \), respectively. Kaplan-Meier and cumulative incidence function plots showed higher risk in eGFR categories G4 and G5 (Fig. 1a, b). Compared to those with eGFR categories G1 and G2, multivariate analyses showed that, after adjusting for established prognosticators and total rehospitalizations, the subset of patients with eGFR categories G4 and G5 remained associated with the higher risk of all-cause (hazard ratio [HR] = 1.15, 95% CI: 1.02–1.30, \( p = 0.020 \)) and CV mortality (HR = 1.20, 95% CI: 1.04–1.39, \( p = 0.013 \)) (Fig. 2). Patients with eGFR categories G3b and G3a did not show an adjusted increase of risk of all-cause (HR = 0.98, 95% CI: 0.89–1.08, and HR = 1.00, 95% CI: 0.91–1.10, respectively) and CV mortality (HR = 1.02, 95% CI: 0.90–1.15, and HR = 1.02, 95% CI: 0.90–0.17), respectively (Fig. 2).

We registered 9,281, 5,387, and 4,139 total all-cause, CV-related, and HF-related readmissions in 3,145, 2,346, and 1,880 patients during the follow-up, respectively. There was a stepwise increase in the risk of recurrent total...
all-cause, CV-related, and HF-related hospitalizations when moving from lower to higher GFR categories (Table 2). Multivariate analyses adjusting for established CV risk factors and controlling for death as a competing event confirmed that the higher the eGFR category, the higher the risk of total all-cause, CV-related, and HF-related readmissions (Fig. 3). Specifically, compared to patients with eGFR categories G1 and G2, those with eGFR categories G4 and G5 displayed a significantly increased risk up to 28%, 26%, and 30% of total all-cause, CV-related, and HF-related readmissions, respectively.

**Discussion**

In this large contemporary cohort of patients hospitalized for AHF, we identify three major findings: (1) Approximately 12% of patients had eGFR categories G4 and G5 at admission. (2) Patients with eGFR categories G4 and G5 were significantly and independently associated with higher long-term mortality. (3) Despite this increased risk of death, patients with lower eGFR categories on admission (particularly G4 and G5) also had an increased risk of total all-cause, CV-related, and HF-related readmissions.

HF and CKD frequently coexist as a consequence of overlapping pathophysiology (i.e., CRS) [10, 11] or as a result of shared cardiometabolic risk factors that drive both disease states in parallel [12, 13]. In the current study, eGFR categories G4 and G5 at admission were pre-

---

**Table 2. Rates of all-cause and the specific cause of readmission across eGFR categories**

| All-cause readmissions | G1-G2 (eGFR ≥60 mL·min⁻¹·1.73 m⁻²) | G3a (eGFR 45–59 mL·min⁻¹·1.73 m⁻²) | G3b (eGFR 30–44 mL·min⁻¹·1.73 m⁻²) | G4-5 (eGFR <30 mL·min⁻¹·1.73 m⁻²) |
|------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| CV readmissions        | G1-G2 (eGFR ≥60 mL·min⁻¹·1.73 m⁻²) | G3a (eGFR 45–59 mL·min⁻¹·1.73 m⁻²) | G3b (eGFR 30–44 mL·min⁻¹·1.73 m⁻²) | G4-5 (eGFR <30 mL·min⁻¹·1.73 m⁻²) |
| HF readmissions        | G1-G2 (eGFR ≥60 mL·min⁻¹·1.73 m⁻²) | G3a (eGFR 45–59 mL·min⁻¹·1.73 m⁻²) | G3b (eGFR 30–44 mL·min⁻¹·1.73 m⁻²) | G4-5 (eGFR <30 mL·min⁻¹·1.73 m⁻²) |

HF, estimated glomerular filtration rate.
dominantly observed in patients with a worst NYHA functional class and higher NT-proBNP values. Although these findings cannot reveal the exact pathophysiological mechanisms behind them, we speculate that some of the connection is related to the inability of the more diseased kidneys to handle the myriad of hemodynamic and non-hemodynamic stressors commonly present in AHF, together with the negative impact of increased left- and right-sided filling pressures on intrarenal hemodynamics. Moreover, patients with eGFR categories G4 and G5 at admission were predominantly female exhibiting a high prevalence of traditional CV risk factors (including T2DM and hypertension) and preserved LVEF. This patient population commonly have a higher prevalence of oxidative stress [14], inflammation [15], and endothelial dysfunction [16], which are well-known risk factors for kidney disease progression [17, 18]. When taken together, our results are consistent with the emerging “cardio-renal phenotype”, characterized by CKD, congestion, and preserved LVEF [19].

Some studies have demonstrated that eGFR on admission independently predicts future adverse events in patients hospitalized for AHF [20–22]. Nonetheless, most of the evidence in this field has evaluated the risk using time-to-first-event methods, with AC mortality as the main terminal event [23]. However, patients with AHF and impaired eGFR commonly represent a highly comorbid population with an increased risk of recurrent admissions and in whom non-CV deaths account for a substantial proportion of deaths [24]. In these scenarios, recent initiatives advocate for a more comprehensive approach evaluating disease-specific causes of death and accounting for all hospitalizations during follow-up to provide a more “realistic” picture of the disease burden [25]. To the best of our knowledge, this is the first study evaluating the total morbidmortality risk profile of eGFR categories on admission in patients hospitalized for AHF through recurrent events methodology.

Consistent with previous data [23], we also found an increased risk of all-cause and CV-related mortality among...
patients with AHF and impaired eGFR. Interestingly, and despite this increased risk of death, patients with AHF and eGFR categories G4 and G5 also showed a higher burden of total all cause (28%), CV related (26%), and HF related (30%) compared to patients with eGFR categories G1 and G2.

There are likely multiple and interdependent mechanisms that may explain this increased morbimortality risk burden. First, patients with the lower eGFR categories showed clinical and biochemical data of a more advanced disease, which may explain the observed increased risk. Second, the management of fluid overload in patients with AHF and eGFR categories G4 and G5 is often challenging because of the higher prevalence of diuretic resistance [26] and the common misinterpretation of creatinine changes during decongestion [5]. For instance, a moderate increase in plasma creatinine during decongestive therapy in a patient with severely impaired eGFR often prompts physicians to reduce diuretic doses, based on the false assumption that further decongestion might accelerate kidney disease or damage [27, 28]. As a result of this “nephroprotective approach,” patients with eGFR categories G4 and G5 are prone to be discharged with residual congestion, which is a well-known risk factor for adverse outcomes [29]. Third, in the present cohort, the use of disease-modifying therapies was markedly lower among those with eGFR categories G4 and G5. Even though the often fluctuating and somewhat uncertain trajectory of kidney function after discharge may partially explain the low prescription rates due to concerns for side effects, the lack of solid evidence of benefit from randomized clinical trials in subjects with eGFR categories G4 and G5 is a significant barrier to its use [30]. Furthermore, the perception of limited life expectancy and competing geriatric syndromes commonly present in this patient population may also drive the underutilization of life-saving therapies. Fourth, clinical cardiologists and HF specialists often ignore additional kidney-specific risk factors, such as iron deficiency, disturbances of calcium-phosphate metabolism, and acid-base disorders, which are well-known drivers of CV and kidney disease progression [31–33].

Overall, there is a risk-treatment paradox in the management of patients with AHF and advanced CKD or kidney failure, such that patients with the highest morbimortality burden are treated with less disease-modifying medical therapies [34]. Therefore, patients with eGFR categories G4 and G5 suffering from an episode of AHF represent one of the most important subgroups that could benefit from cardiorenal-specific programs aimed to personalize care and reduce readmission and mortality risk burden [35].

**Limitations**

Our study has several limitations that need to be highlighted: (1) The present study is observational in nature and, consequently, exposed to different types of bias and residual confounding; (2) we included only patients with AHF, so our conclusions do not apply to patients with stable CHF; (3) the adjudication of the specific cause of death and readmissions was mainly done using the patient’s chart review of electronic medical records, which may introduce some error in the competing risk estimates; (4) we used only the eGFR as a marker of kidney function, which could limit the study’s precision; (5) eGFR at discharge was not available in a substantial proportion of study participants. Accordingly, we could not formally evaluate the differential prognostic value of eGFR categories between the two time-points; and (6) although the results were obtained from a large population at three different tertiary hospitals, further studies are necessary to quantify the morbimortality burden attributable to impaired kidney function in other healthcare scenarios.

**Conclusions**

In summary, eGFR categories G4 and G5 (representing advanced CKD and kidney failure, respectively) are frequent at admission in patients hospitalized for AHF and are associated with higher long-term mortality and morbidity burdens.

**Acknowledgments**

The authors thank nurses of the three hospitals.

**Statement of Ethics**

The study protocol was approved by the Institutional Review Board of the Ethical Committee (approval number: 283) and was conducted in accordance with the principles of the Declaration of Helsinki. All subjects have given their written informed consent.

**Conflict of Interest Statement**

Rafael de la Espriella, Pau Llàcer, and Julio Núñez received board speaker fees and travel expenses from Novartis, Rovi, Pfizer, Daiichi Sankyo, AstraZeneca, NovoNordisk, Boehringer Ingelheim, and Lilly. Antoni Bayés-Genís reports honoraria for lectures and/or consulting from Abbott, AstraZeneca, Boehringer Ingelheim, Critical Diagnostics, Novartis, Roche Diagnostics, and Vifor. Patricia Palau received board membership fees, speaker fees, and
consulting fees from Boehringer Ingelheim, Menarini, and Novartis. Gema Miñana received speaker fees and travel expenses from Abbott. Enrique Santas received board speaker fees and travel expenses from Novartis, Rovi, Pfizer, Daiichi Sankyo, AstraZeneca, Novo Nordisk, and Boehringer Ingelheim. Jose Luis Górriz received board membership fees, speaker fees, and consulting fees from Astra Zeneca, Boehringer-Ingelheim, Lilly, Janssen, Mundipharma, Menarini, and Novonordisk. Javier Diez received board membership fees, speaker fees, and consulting fees from AstraZeneca, Bayer, and Vifor. All other authors declare no competing interests.

**Funding Sources**

This work was supported by Project PI13/01519 in collaboration with “Plataforma de Unidades de Investigación Clínica y Ensayos Clínicos” (SCReN) (PT13/0002/0031); co-funded by “Fondos FEDER”; unrestricted grants from “Proyectos de Investigación de Insuficiencia Cardiaca de la Sección de Insuficiencia Cardiaca 2015” and “Beca Mutual Médica 2014”; PIE15/00013; and CIBER CV 16/11/00420 and 16/11/00403. The funder has no role in the study design, data collection, analysis and modeling, interpretation of the results, and in writing the manuscript.

**References**

1. Tedeschi A, Agostoni B, Pezzuto B, Corra’ U, Scutinio D, La Gioia R, et al. Role of comorbidities in heart failure prognosis. J Am Coll Cardiol. 2016;68(5):426–35.

2. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J, et al. High prevalence of renal dysfunction and its impact on outcome in 118, 465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–30.

3. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CSP, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–93.

4. Beldhuis IE, Streng KW, van der Meer P, Ter Maaten JM, O’Connor CM, Metra M, et al. Trajectories of changes in renal function in patients with acute heart failure. J Card Fail. 2019;25(11):666–74.

5. Mullens W, Damman K, Testani JM, Martens P, Mueller G, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584–603.

6. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

7. Hicks KA, Mahafey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. Standardized data collection for cardiovascular trials initiative (SCTI). 2017 cardiovascular and stroke endpoint definitions for clinical trials. J Am Coll Cardiol. 2018;71(9):1021–34.

8. Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Cheung M, Jadoul M, et al. Nomenclature for kidney function and disease-executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Eur Heart J. 2020;41(48):4592–8.

9. Xu X, Hardin JW. Regression models for bivariate count outcomes. Stata J. 2016;16(2):301–15.

10. Rangawani J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139(16):e840–78.

11. Núñez J, Miñana G, Santas E, Bertomeu-González V. Cardiorenal syndrome in acute heart failure: revisiting paradigms. Rev Esp Cardiol. 2015;68(5):426–35.

12. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–39.

13. Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis. 2018;25(3):382–90.

14. Uijl A, Savarese G, Vaartjes I, Dahlström U, Brugs J, Linnen GCM, et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(6):973–82.

15. Sanders-van Wijk S, Tromp J, Beusink-Nelson L, Hage C, Svedlund S, Saraste A, et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFPEF study. Circulation. 2020;142(21):2029–44.

16. Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail. 2016;18(6):588–98.

17. Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail. 2020;22(9):1551–67.

18. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786–802.

19. Shah SJ. Precision medicine for heart failure with preserved ejection fraction: an overview. J Cardiovasc Transl Res. 2017;10(3):233–44.

20. Brandomarte F, Vaduganathan M, Mureddu GF, Cacciarelli G, Sabbah HN, Fonarow GC, et al. Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations. Heart Fail Rev. 2013;18(2):167–76.

21. Metra M, Voors AA. The puzzle of kidney dysfunction in heart failure: an introduction. Heart Fail Rev. 2012;17(2):129–31.

**Author Contributions**

Rafael de la Espriella, Jorge Navarro, and Julio Núñez: conception and design of the study. Julio Núñez and Rafael de la Espriella: analysis and interpretation of data and drafting the article. Anna Mollar, Luis D’Marco, Patricia Palau, Gema Miñana, Pau Llácer, Enrique Santas, Raquel Heredia, and Miguel González: acquisition of data. Antoni Bayés-Genis, José Luis Górriz, Pau Codina, and Javier Diez: revising the article critically for important intellectual content. All authors: final approval of the version to be submitted.

**Data Availability Statement**

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

---

Cardiorenal Med 2022;12:179–187
DOI: 10.1159/000526105

de la Espriella et al.
22 Kajimoto K, Sato N, Takano T; ATTEND investigators. eGFR and outcomes in patients with acute decompensated heart failure with or without elevated BUN. *Clin J Am Soc Nephrol*. 2016;11(3):405–12.

23 Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. *Eur Heart J*. 2014;35(7):455–69.

24 Giamouzis G, Kalogeropoulos AP, Butler J, Karayannis G, Georgiopoulou VV, Skoularigis J, et al. Epidemiology and importance of renal dysfunction in heart failure patients. *Curr Heart Fail Rep*. 2013;10(4):411–20.

25 Anker SD, McMurray JJV. Time to move on from “time-to-first”: should all events be included in the analysis of clinical trials? *Eur Heart J*. 2012;33(22):2764–5.

26 Wilcox CS, Testani JM, Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. *Hypertension*. 2020;76(4):1045–54.

27 McCallum W, Tighiouart H, Testani JM, Griffin M, Konstam MA, Udelson JE, et al. Acute kidney function declines in the context of decongestion in acute decompensated heart failure. *JACC Heart Fail*. 2020;8(7):537–47.

28 Wettersten N, Horiuchi Y, van Veldhuisen DJ, Ix JH, Mueller C, Filippatos G, et al. Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure. *Eur J Heart Fail*. 2021;23(7):1122–30.

29 Lala A, McNulty SE, Mentz RJ, Dunlay SM, Vader JM, AboutEzeddine OF, et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). *Circ Heart Fail*. 2015;8(4):741–8.

30 House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, et al. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2019;95(6):1304–17.

31 Langote A, Ahearn M, Zimmerman D. Dialysate calcium concentration, mineral metabolism disorders, and cardiovascular disease: deciding the hemodialysis bath. *Am J Kidney Dis*. 2015;66(2):348–58.

32 Cubbon RM, Thomas CH, Drozd M, Gierula J, Jamil HA, Byrom R, et al. Calcium, phosphate and calcium phosphate product are markers of outcome in patients with chronic heart failure. *J Nephrol*. 2015;28(2):209–15.

33 Goldsmith DJA, Cunningham J. Mineral metabolism and vitamin D in chronic kidney disease: more questions than answers. *Nat Rev Nephrol*. 2011;7(6):341–6.

34 Patel RB, Fonarow GC, Greene SJ, Zhang S, Alhanti B, DeVore AD, et al. Kidney function and outcomes in patients hospitalized with heart failure. *J Am Coll Cardiol*. 2021;78(4):330–43.

35 Banerjee D, Wang AYM. Personalizing heart failure management in chronic kidney disease patients. *Nephrol Dial Transpl*. 2021;gfab026.